Could a common immune treatment help preemies breathe easier?

NCT ID NCT06925360

Recruiting now Disease control Sponsor: International Peace Maternity and Child Health Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether intravenous immunoglobulin (IVIG) can treat bronchopulmonary dysplasia (BPD), a chronic lung disease in premature infants. Twenty babies born between 25 and 30 weeks will receive IVIG infusions over five days. Researchers will check if the treatment reduces the severity of BPD and shortens the need for breathing support.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intravenous immunoglobulin (IVIG)
What this could lead to: If it works, this could point toward a treatment that reduces lung damage and breathing problems in premature babies with bronchopulmonary dysplasia.
What could go wrong: This is a very early, small trial with only 20 babies, so results may not be conclusive. IVIG can cause side effects like allergic reactions or kidney issues, and the treatment may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHOPULMONARY DYSPLASIA

Contacts and locations

Locations

International Peace Maternity and Child Health Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.